Navigation Links
Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Date:4/24/2012

MALVERN, Pa., April 24, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Deutsche Bank 37th Annual Healthcare Conference to be held May 7-9, 2012 at the InterContinental Hotel in Boston.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:40 a.m. ET on Tuesday, May 8, 2012.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

The presentation slides to be used during the call will be available on the "For Investors" section of the Auxilium website under the "Presentations" tab on May 8, 2012.  The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on May 8, 2012 and a breakout session will follow the presentation.  To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.  The presentation replay will be available for ninety days after the event.About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) and is in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the 37th Annual Deutsche Bank 37th Annual Healthcare Conference; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, which is on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR  Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

wsargent@auxilium.com


'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
2. Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference
3. Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference
4. BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
5. Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico
6. Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
8. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
10. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. Announces Publication of U.S. CPT® Codes and Related Reimbursement Rates for XIAFLEX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... PALO ALTO, Calif. (PRWEB) , ... February 21, 2020 , ... ... Analysis (ABA) solutions. The company is passionate about changing the lives of ... a grant consortium in California focused on helping people find employment opportunities. Special ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... Enquire, a ... living and post-acute care, is proud to announce G5 as a Silver Sponsor of ... , “G5 is proud to return to Enquire Summit as a Silver Sponsor. This ...
(Date:2/19/2020)... ... , ... A new study released today in STEM CELLS Translational Medicine is ... a compressed spinal cord. It is also the first to show how transplanting basic ... enhances the injured spinal cord’s recovery. , The study, conducted on a rat ...
Breaking Medicine Technology:
(Date:2/26/2020)... ... February 26, 2020 , ... ... platforms company Transposagen (now a Hera BioLabs company) which is best known for ... and dual-guided CRISPR nickase systems as it is truly dimeric and demonstrates high ...
(Date:2/26/2020)... ... February 26, 2020 , ... RosettaHealth , an ... its new HealthBus Worklflows solution, which will be showcased at HIMSS20 in booth ... health data exchange workflows to scenarios in days using a collection of pre-built ...
(Date:2/21/2020)... LAKES, Fla. (PRWEB) , ... February 21, 2020 ... ... today announced that it is now offering a 10 percent grand opening discount ... get 10 percent off all purchases," said Osmay Gonzalez, spokesperson for Baby Blendy ...
(Date:2/21/2020)... ... 2020 , ... The American Society for Clinical Pathology (ASCP) ... MA, in October 2021. The prestigious, invitation-only event—organized by the Union for International ... health, city and industry leaders, senior executives and other influential players from ...
(Date:2/20/2020)... ... ... Millennial women are flocking to cosmetic surgeons like Dr. Richard E. Buckley ... achieve “ Rich Girl Face .” In fact, Glamour magazine called it the cosmetic ... It’s a look inspired by the signature bee-stung lips, smooth skin, lifted eyebrows and ...
Breaking Medicine News(10 mins):